ARENA, FLAVIA
 Distribuzione geografica
Continente #
NA - Nord America 143
EU - Europa 117
AS - Asia 107
SA - Sud America 18
AF - Africa 3
Totale 388
Nazione #
US - Stati Uniti d'America 134
IT - Italia 38
CN - Cina 37
SG - Singapore 32
RU - Federazione Russa 20
HK - Hong Kong 19
DE - Germania 18
FI - Finlandia 18
BR - Brasile 12
VN - Vietnam 8
CA - Canada 5
PL - Polonia 5
ES - Italia 4
GB - Regno Unito 4
IN - India 4
VE - Venezuela 4
ZA - Sudafrica 3
AT - Austria 2
BD - Bangladesh 2
JM - Giamaica 2
LT - Lituania 2
MX - Messico 2
SA - Arabia Saudita 2
AL - Albania 1
CO - Colombia 1
FR - Francia 1
IE - Irlanda 1
JP - Giappone 1
KG - Kirghizistan 1
LV - Lettonia 1
NL - Olanda 1
SE - Svezia 1
TR - Turchia 1
UY - Uruguay 1
Totale 388
Città #
Dallas 32
Singapore 21
Hong Kong 19
Ashburn 16
Beijing 13
Munich 12
New York 12
Helsinki 10
Rome 9
Shanghai 9
Boardman 8
Los Angeles 8
Turku 8
Milan 7
Moscow 6
Düsseldorf 4
Warsaw 4
Brooklyn 3
Buffalo 3
Chennai 3
Houston 3
Seattle 3
Toronto 3
Charlotte 2
Denver 2
Hanoi 2
Johannesburg 2
Montreal 2
Orem 2
Redondo Beach 2
Santa Clara 2
Serrone 2
The Dalles 2
Vilnius 2
Washington 2
Amsterdam 1
Ankara 1
Araçoiaba da Serra 1
Betim 1
Bishkek 1
Boves 1
Bắc Giang 1
Can Tho 1
Catanduva 1
Changsha 1
Chicago 1
Chongqing 1
Columbus 1
Delhi 1
Dublin 1
El Dorado 1
Extrema 1
Haiphong 1
Ho Chi Minh City 1
Itajaí 1
Jacksonville 1
Jequié 1
Jinan 1
Lauterbourg 1
London 1
Magé 1
Maracaibo 1
Maracay 1
Marshfield 1
Medellín 1
Medina 1
Mexico City 1
Montevideo 1
Mérida 1
Pavia 1
Phoenix 1
Poplar 1
Querétaro 1
Ribeirão Preto 1
Riga 1
Riyadh 1
Shenyang 1
Stockholm 1
Tapejara 1
Teresina 1
Tokyo 1
Uberlândia 1
Wroclaw 1
Totale 288
Nome #
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 94
Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers 73
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 62
Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients 60
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment 59
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern 46
Totale 394
Categoria #
all - tutte 2.114
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.114


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202320 0 0 0 0 0 0 0 0 8 1 11 0
2023/202479 6 15 6 1 5 28 8 3 0 3 0 4
2024/2025123 5 7 1 2 2 11 8 3 27 12 17 28
2025/2026172 25 16 38 41 32 20 0 0 0 0 0 0
Totale 394